You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 15, 2024

CLINICAL TRIALS PROFILE FOR SEVELAMER HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SEVELAMER HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018135 ↗ Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals Completed National Center for Research Resources (NCRR) N/A 1969-12-31 Patients on hemodialysis tend to have chronic elevations in the level of phosphorus in the blood and a secondary increase in the iPTH level. This chronic elevation in iPTH can have adverse consequences, thus a variety of phosphate binders are given in an attempt to decrease the absorption of phosphorus present in the normal diet. Some preliminary studies have indicated that the iPTH level may change based on the amount of phosphorus present in a meal prior to any significant absorption of phosphorus. If this is true in hemodialysis patients, then the timing of the administration of phosphate binders in relation to the ingestion of meals needs to be considered
NCT00151918 ↗ Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease Completed Shire Phase 3 2005-01-07 The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with either lanthanum carbonate or sevelamer hydrochloride
NCT00196755 ↗ Study of Safety and Efficacy of RenagelĀ® Compared With Calcium Acetate in Patients With Peritoneal Dialysis Completed Genzyme, a Sanofi Company Phase 3 2004-12-01 The purpose of this study is to demonstrate that sevelamer hydrochloride is non-inferior to calcium acetate for the treatment of hyperphosphataemia in patients receiving peritoneal dialysis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SEVELAMER HYDROCHLORIDE

Condition Name

Condition Name for SEVELAMER HYDROCHLORIDE
Intervention Trials
Hyperphosphatemia 22
Chronic Kidney Disease 19
Kidney Failure, Chronic 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SEVELAMER HYDROCHLORIDE
Intervention Trials
Kidney Diseases 44
Renal Insufficiency, Chronic 39
Hyperphosphatemia 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SEVELAMER HYDROCHLORIDE

Trials by Country

Trials by Country for SEVELAMER HYDROCHLORIDE
Location Trials
United States 160
France 18
China 17
United Kingdom 16
Japan 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SEVELAMER HYDROCHLORIDE
Location Trials
New York 13
California 12
Texas 11
Illinois 10
Colorado 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SEVELAMER HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for SEVELAMER HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 13
Phase 3 24
Phase 2 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SEVELAMER HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 58
Unknown status 7
Terminated 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SEVELAMER HYDROCHLORIDE

Sponsor Name

Sponsor Name for SEVELAMER HYDROCHLORIDE
Sponsor Trials
Genzyme, a Sanofi Company 19
Shire 8
Fresenius Medical Care North America 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SEVELAMER HYDROCHLORIDE
Sponsor Trials
Industry 59
Other 52
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.